Literature DB >> 19475556

Dielectric relaxation study on tramadol monohydrate and its hydrochloride salt.

K Kaminski1, E Kaminska, K Adrjanowicz, K Grzybowiska, P Wlodarczyk, M Paluch, A Burian, J Ziolo, P Lepek, J Mazgalski, W Sawicki.   

Abstract

Dielectric relaxation measurements as well as differential scanning calorimetry and X-ray diffraction investigations were performed on tramadol monohydrate and its hydrochloride salt. Examined samples do not crystallize during cooling and in consequence they reach the glassy state. In the case of the hydrochloride tramadol we are able to monitor alpha-relaxation process despite large contribution of dc conductivity to the loss spectra. It is the first such study on the salt of the drug. Up to now the dielectric spectroscopy has been regarded as useless in measuring such kind of API (active pharmaceutical ingredient). In this paper we also made some suggestions about the nature of the secondary relaxations in the amorphous tramadol monohydrate and its salt. The knowledge about the molecular mechanisms, which govern the observed secondary relaxations seems to be the key in predicting the stability of the amorphous form of the examined API. Finally additional dissolving measurements on the amorphous and crystal tramadol hydrochloride were performed. As a result we understood that dissolution properties of the amorphous form of the considered drug are comparable to those of crystalline one. However, we have found out that amorphous tramadol hydrochloride has greater ability to form tablets than its crystalline equivalent. This finding shows that amorphous drugs can be alternative even for the freely solved pharmaceuticals such as tramadol hydrochloride, because the former one has better ability to form tablets. It implies that during tabletting of the amorphous drugs there is no need to use any excipients and chemicals improving compaction properties of the API.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19475556     DOI: 10.1002/jps.21799

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  The improvement of the dissolution rate of ziprasidone free base from solid oral formulations.

Authors:  Daniel Zakowiecki; Krzysztof Cal; Kamil Kaminski; Karolina Adrjanowicz; Lech Swinder; Ewa Kaminska; Grzegorz Garbacz
Journal:  AAPS PharmSciTech       Date:  2015-01-16       Impact factor: 3.246

2.  Enhancement of the physical stability of amorphous indomethacin by mixing it with octaacetylmaltose. inter and intra molecular studies.

Authors:  E Kaminska; K Adrjanowicz; D Zakowiecki; B Milanowski; M Tarnacka; L Hawelek; M Dulski; J Pilch; W Smolka; I Kaczmarczyk-Sedlak; K Kaminski
Journal:  Pharm Res       Date:  2014-05-15       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.